Chair: Rachel Batterham (GBR)
| 16:30 – 16:35 | Welcome and Introduction | Rachel Batterham (GBR) |
| 16:35 – 16:45 | Empowering Change: The Need for Proactive, Comprehensive Treatment for T2D and Obesity | Andreea Ciudín (ESP) |
| 16:45 – 16:55 | Targeting Adiposity as a Root Cause of T2D and Obesity | Timo Müller (DEU) |
| 16:55 – 17:10 | Mounjaro for the Treatment of T2D: SURPASS Program | Santiago Tofé (ESP) |
| 17:10 – 17:25 | Mounjaro for the Treatment of Obesity: SURMOUNT-1 | Luc Van Gaal (BEL) |
| 17:25 – 17:40 | Real Patient Experiences With Mounjaro | Matthew Capehorn (GBR) Khadija Hafidh (ARE) |
| 17:40 – 17:55 | Panel Discussion and Q&A | All Faculty |
| 17:55 – 18:00 | Closing Remarks | Rachel Batterham (GBR) |
▼This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions associated with this medicinal product is a priority. ▼Este medicamento está sujeto a seguimiento adicional, es prioritaria la notificación de sospechas de reacciones adversas asociadas a este medicamento.
All Mounjaro presentations and doses may not be available in all countries. Puede que no todas las dosis y tamaños de envases estén comercializadas en todos los países.
Mounjaro (tirzepatide) [Summary of Product Characteristics]. Eli Lilly The Netherlands B.V.
- Monday, 9 September 2024
- 16:30 - 18:00 CEST
- Sydney Hall
